Introduction Implantation of an automatic cardioverterdefibrillator
|
|
- Gwen Annice Todd
- 5 years ago
- Views:
Transcription
1 Excellent Long-Term Reproducibility of the Electrophysiologic Efficacy of Quinidine in Patients with Idiopathic Ventricular Fibrillation and Brugada Syndrome BERNARD BELHASSEN, M.D., AHARON GLICK, M.D., and SAMI VISKIN, M.D. From the Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel Background: Quinidine is very effective in preventing the reinduction of sustained ventricular fibrillation (VF) during electrophysiologic study (EPS) in patients with idiopathic VF and Brugada syndrome. However, there are no data on the long-term reproducibility of this EP efficacy. Methods and Results: Nine patients (seven males and two females, aged years), who suffered from aborted cardiac arrest (n = 8) or recurrent syncope (n = 1) due to Brugada syndrome (n = 5) or idiopathic VF (n = 4), comprised the study. All patients had inducible sustained VF at baseline that was prevented by quinidine therapy and underwent another EPS on medication after (9.8 ± 6.8) years (>5 years in eight patients). Two patients underwent two late EPS on quinidine. The goal of repeat EPS on quinidine was to ensure persistent long-term drug efficacy (n = 6) or to elucidate the reason of syncopal episodes during therapy (n = 3). The EPS protocol significantly evolved over the years as it became more aggressive (more pacing sites and/or more ventricular extrastimuli). All nine patients tolerated the medication well and had no recurrent documented arrhythmic events during long-term follow-up (mean 15 ± 7 years). No sustained ventricular tachyarrhythmias could be induced in any patient during repeat late EPS. In six patients, a more aggressive stimulation protocol could be tested at repeat EPS. Conclusion: The long-term reproducibility of the EP efficacy of quinidine in patients with idiopathic VF and Brugada syndrome is excellent. EP-guided quinidine therapy represents a valuable long-term alternative to ICD therapy in these patients. (PACE 2009; 32: ) quinidine, electrophysiologic study, programmed ventricular stimulation, idiopathic ventricular fibrillation, Brugada syndrome Introduction Implantation of an automatic cardioverterdefibrillator (ICD) is recommended by most cardiac electrophysiologists worldwide in patients with ventricular fibrillation (VF) occurring in patients without organic heart disease (idiopathic VF) and those affected with the Brugada syndrome. 1,2 Antiarrhythmic therapy with quinidine is frequently used as an adjuvant to control recurrent ventricular arrhythmias in implanted patients. 3,4 The policy at our institution during the last three decades concerning these patients has been different and based on our published experience 5 7 showing: (1) the great efficacy of quinidine in preventing reinduction of sustained ventricular tachyarrhythmias during electrophysiology study (EPS), and (2) the excellent long-term clinical out- No disclosure. Address for reprints: Bernard Belhassen, M.D., Department of Cardiology, Tel-Aviv Sourasky Medical Center, Weizman Street 6, Tel-Aviv 64239, Israel. Fax: ; bblhass@tasmc.health.gov.il Received April 28, 2008; revised August 4, 2008; accepted September 18, come of the patients treated with the drug. Thus, we usually have left the patient the choice between implantable cardioverter-defibrillator (ICD) therapy and EP-guided chronic quinidine therapy. 8 However, there is only scarce information available about the long-term EP efficacy of quinidine. In this study, we review our experience on the long-term EP efficacy of quinidine in a group of patients who underwent EP-guided quinidine therapy for idiopathic malignant ventricular tachyarrhythmias. Methods Patient Selection Records of all patients with inducible sustained VF during EPS were reviewed. Criteria for inclusion in the study included all the following: (1) no recognizable heart disease based on normal findings during noninvasive (echocardiogram, exercise test, Thallium test) and/or invasive (right and left ventriculography and coronary angiography) evaluation, (2) normal baseline QT interval on repeated electrocardiograms (ECGs), (3) EP testing with quinidine showing no inducible sustained ventricular arrhythmias, (4) long-term treatment with quinidine following the initial C 2009, The Authors. Journal compilation C 2009 Wiley Periodicals, Inc. 294 March 2009 PACE, Vol. 32
2 QUINIDINE FOR IDIOPATHIC VF AND BRUGADA SYNDROME drug testing, and (5) repeat EP testing on quinidine 1 year following the first drug study. From February 1979 to December 2007, 76 patients (87% males, 38% with spontaneous VF) with inducible VF and no obvious heart disease underwent repeat EP testing with quinidine in our laboratory. In 71 (93.4%) of these patients, quinidine bisulphate (750 2,000 mg/day) effectively prevented the reinduction of sustained ventricular arrhythmias. Nine (12.6%) of the 71 patients underwent repeat EPS on quinidine >1 year after the initial drug testing and comprised the study group. The case report of one of the patients has been reported elsewhere. 9,10 All the study patients were included in our previous publications. 5 7 EPS Protocol EPSs were performed using a protocol of programmed ventricular stimulation (PVS) that evolved over the years. From 1979 to 1982, PVS was performed only from the right ventricular apex, using three basic cycle lengths (600, 500, and 400 ms) and a maximum of two extrastimuli. In 1983, pacing from the right ventricular outflow tract (RVOT) was added and the number of basic cycle lengths was decreased to two (usually 600 and 400 ms). The use of triple extrastimulation in our laboratory was introduced in In addition, our protocol has included repetition (10 times) of double extrastimulation (since 1979) and repetition (five times) of triple extrastimulation (since 1988) both at the shortest coupling intervals. This was done at each pacing site and for each of the cycle lengths tested. We previously found that repetition of extrastimulation increases the sensitivity of PVS protocols. 11 The stimulus current intensity was set at five times the diastolic threshold (but never >3 ma). Definitions Sustained VF was a ventricular tachyarrhythmia manifesting a continuously varying morphology with a mean cycle length <200 ms that required cardioversion for termination or resulted in clinical cardiac arrest before spontaneous termination. Nonsustained ventricular tachycardia (NSVT) was a tachycardia of 6 complexes that was shorter than 30 seconds in duration and was not associated with loss of consciousness. Arrhythmias were noninducible when <6 repetitive ventricular complexes were induced. Results Study Patients (Table I) The study group comprised nine patients, seven males and two females, ranging in age from 21 to 72 (40 ± 16.5) years (Table 1). Five patients Table I. Results of Electrophysiological Drug Testing in Nine Patients EPS No. 1 EPS No. 2 EPS No. 3 Quinidine Bisulphate Quinidine Bisulphate Quinidine Bisulphate Pt S/A Diagnosis Date Dose BL Results Date Dose BL Results Date Dose BL Results 1 M 28 IVF 5/4/79 1, NI 7/11/02 1, NSVT(7) 2 M 52 VF + BS 22/11/81 1, NI 14/7/92 1,500 NA NI 3 F 24 VF + BS 27/2/85 1, NSVT(7) 3/9/02 1,500 NA NSVT(60) 4 M 27 IVF 16/11/87 1, NI 11/7/95 1, NI 5 M 40 IVF 4/2/92 1, NI 13/2/99 1, NSVT(34) 6 M 21 VF + BS 31/7/94 1, NSVT(9) 13/7/99 1,500 NA NSVT(15) 13/6/02 1, NSVT(24) 7 M 43 VF + BS 22/11/94 1, NI 23/11/99 1, NSVT(14) 16/2/06 1, NSVT(7) 8 F 51 IVF 2/12/97 1, NI 23/10/07 600* 1.2 NI 9 M 72 Syncope + BS 23/9/ NSVT(17) 24/5/ NA NI Abbreviations: A = age; BL = blood level (mg/l); BS = Brugada syndrome; F = female; IVF = idiopathic ventricular fibrillation; NI = noninducible; M = male; NA = nonavailable; NSVT = nonsustained ventricular tachycardia; Pt = patient; S = sex; * = quinidine hydrochloride. PACE,Vol.32 March
3 BELHASSEN, ET AL. Figure 1. ECG tracings obtained at hospital admission (November 24, 1997) of a 57-year-old woman with a history of multiple syncopes (no. 10) during the few weeks prior to admission. Ventricular extrasystoles of variable coupling interval (some of them very short coupled) are seen in panel A. Panel B shows an episode of rapid nonsustained polymorphic ventricular tachycardia, triggered by a very short coupled ventricular extrasystole. In panel C, a similar long-lasting episode resulting in syncope is shown. (one female) had Brugada syndrome and four patients had idiopathic VF. Eight patients had cardiac arrest with documented VF (Fig. 1) and one patient with the Brugada syndrome had recurrent syncope of unknown cause. Initial EPS on Quinidine (Table I) In all nine patients who had inducible sustained VF at baseline, no sustained ventricular tachyarrhythmias could be induced during treatment with quinidine bisulfate (Quiniduran,* Teva Laboratories, Tivka, Israel) at doses ranging from 750 mg (one patient) to 1,500 mg (eight patients) (Figs. 2 and 3). The effective quinidine serum blood levels ranged from 1.3 to 6.2 mg/l (mean 3.5 ± 1.6 mg/l). In six of these nine patients, no significant arrhythmias were induced while asymptomatic NSVT including 7 17 beats was induced in the remaining three patients. Repeat EPS on Quinidine (Table I) Repeat EP study was performed in all nine patients after (9.8 ± 6.8) years of quinidine therapy ( 5 years in eight of nine patients). The goal of the repeat EPS on quinidine was to ensure persistent long-term drug efficacy (n = 7 patients) or to elucidate the reason of syncopal episodes during therapy (n = 2; patients 5 and 9). In all patients but one, the repeat drug study was performed on the same quinidine salt (bisulphate). In one patient the EPS was performed on hydrochloride quinidine (Serecor,* Sanofi-Aventis Laboratories, Paris, France) due to discontinuation of the production of quinidine bisulphate. 12 In seven of the eight patients who underwent initial and repeat EPS on the same quinidine salt, an identical drug dosage of 1,500 mg/day was tested. In five patients, the serum quinidine levels obtained at the initial and repeat EPS were 3.82 ± 1.65 and 2.39 ± 1.05 mg/l, respectively (P = 0.14 using paired Wilcoxon signed-ranks test). No sustained ventricular tachyarrhythmias could be induced in any of the nine patients during repeat EP testing on quinidine (Figs. 4 and 5). This was observed despite the fact that in four of the nine patients, the PVS protocol was more aggressive at repeat study (triple extrastimulation could be tested at repeat EPS while only double extrastimulation was applied at the initial EPS). Third EPS on Quinidine (Table I) In two of the nine patients (patients 6 and 7), a third EPS was performed during quinidine therapy 3 years and 6 years, respectively, after the second drug study. In patient 7 it was performed to reassess drug efficacy while in patient 6 it was justified by the occurrence of a syncopal episode during quinidine therapy. In both patients, only NSVT could be induced. 296 March 2009 PACE,Vol.32
4 QUINIDINE FOR IDIOPATHIC VF AND BRUGADA SYNDROME Figure 2. Baseline electrophysiologic study (November 25, 1997). Induction of sustained rapid polymorphic ventricular tachycardia with triple extrastimulation from the right ventricular apex. The tachycardia was terminated with DC shock. Clinical Course All nine patients tolerated the medication well during long term and had no recurrent documented arrhythmic events during follow-up ranging from 4.5 to 29 (mean 15 ± 7) years. However, an ICD was implanted in two patients (patients 3 and 6). Patient 3 was 24 years old at the time of initial cardiac arrest. After 17 uneventful years of quinidine therapy, she opted for the ICD option (of note, this patient had two uneventful pregnancies and normal childbirth during quinidine therapy). Patient 6 initially presented with a history of recurrent syncope and had documented VF at the emergency room. He remained asymptomatic for 8 years on 1,500-mg quinidine (which was found effective at two EP studies performed 5 years apart) but later had unexplained syncope that prompted a third EP study on quinidine. Although this study only showed the induction of a 4-second episode of NSVT, it could not be ruled out that that the syncopal episode was due to a spontaneous longer episode of NSVT. Therefore, an ICD was implanted without discontinuing quinidine therapy. Three months and 1 year later, the patient had recurrent syncope but ICD interrogation failed to reveal any arrhythmia in both instances. One patient (no. 2) who had normal coronary angiography in 1981 at the time of his cardiac arrest underwent coronary artery bypass grafting for multivessel disease with preserved left ventricular function 18 years later. All remaining eight patients had no change in their cardiac status during follow-up. Discussion Efficacy of Quinidine In contrast to the present general skepticism of the cardiologic community toward the use of class 1 antiarrhythmic drugs and especially quinidine in patients with ventricular arrhythmias, the literature has shown the extraordinary efficacy of this drug in the treatment of malignant arrhythmias occurring in patients with no demonstrable heart disease. The first patients with idiopathic VF reported, back in 1929 and 1949, were PACE,Vol.32 March
5 BELHASSEN, ET AL. Figure 3. Repeat electrophysiologic study after 1 week of treatment with quinidine bisulfate (1,500 mg/day). No ventricular arrhythmias could be induced with up to five extrastimuli delivered from both the right ventricular apex and the right ventricular outflow tract. treated with quinidine after multiple episodes of spontaneous polymorphic VT and VF were clearly documented. 13,14 Both patients had an excellent response to the medication. Interestingly, a second publication reporting the long-term follow-up of the patient initially reported in 1949 established that this patient eventually died of cancer at old age, without ever experiencing a recurrence of his arrhythmia while on quinidine therapy for 40 years. 15 In addition, quinidine is being successfully used as a first-line therapy for abolishing arrhythmic storms in patients with Brugada syndrome. 3,4 Our group reported the first largest series of patients with idiopathic VF or Brugada syndrome in whom quinidine was found to be very effective (96%) in preventing VF reinducibility during EPS. 6 Similar results were found by others In this study, we report the first series of nine patients with inducible VF in whom the repeat EP efficacy of quinidine was confirmed late (>5 years in eight patients) following the initial drug testing. In patients with Brugada syndrome, the efficacy of quinidine has been attributed to various mechanisms: (1) strong inhibition of Ito current that restores electrical homogeneity and abolishes phase 2 reentry, 2 and (2) anticholinergic effects. In patients with idiopathic VF, the mechanism of the efficacy of quinidine is much obscure. 6 Effect of Stimulation Protocol Our study has spread over three decades, and major changes in the stimulation protocol occurred during this period. Therefore, one could wonder whether the use of more aggressive PVS protocols at repeat drug study would 298 March 2009 PACE,Vol.32
6 QUINIDINE FOR IDIOPATHIC VF AND BRUGADA SYNDROME Figure 4. Repeat electrophysiologic study performed approximately 10 years later during treatment with quinidine hydrochloride (600 mg/day). Only single repetitive ventricular complexes are induced with triple extrastimulation from the right ventricular apex. have revealed drug failure among some patients studied earlier with less aggressive protocols. The results of our study showed that this was not the case. All four patients in whom drug efficacy was first tested with double extrastimulation and who were subsequently tested with more aggressive PVS protocols showed a similar efficacy of quinidine. Figure 5. Same findings as in Figure 4 during programmed ventricular stimulation from the right ventricular outflow tact. PACE,Vol.32 March
7 BELHASSEN, ET AL. Study Limitations Following the first drug study, eight of our nine patients did not develop any change in their cardiac condition during follow-up as expected from the fact they had no obvious heart disease at study inclusion. However, one patient subsequently developed significant coronary artery disease with preserved left ventricular function. Had this patient suffered an acute myocardial infarction during quinidine therapy it might have altered the later EP results. Therefore, close patient follow-up is necessary in order to detect any change in cardiac status or other abnormalities (such as electrolyte disturbances) that may affect the safety of long-term quinidine therapy. Clinical Implications The results of our study suggest that EPguided therapy with quinidine is a very reasonable long-term therapeutic alternative to ICD therapy for patients with idiopathic VF or Brugada syndrome provided several conditions are fulfilled: (1) the patients have inducible VF at baseline EPS, (2) quinidine prevents the reinduction of VF, (3) the patients exhibit a good tolerance to the medication, (4) repeated assertion of drug compliance during follow-up is obtained, (5) the patients are committed to a life-long drug therapy, and (6) no significant change in cardiac status occurs during follow-up. Such a therapeutic option can be safely recommended to patients who refuse the implantation of an ICD or to patients for whom cost constraints resulting from implantation and replacements of ICD over the years will make impossible the ICD option. Other potential candidates are young patients in whom multiple ICD replacements are expected during long term as well as patients in whom ICD needs to be explanted due to complications. Finally, our results suggest that patients with Brugada syndrome and inducible VF, but no previous cardiac arrest, and in whom controversial results presently exist concerning the predictive value of EPS, 22,23 may benefit from the quinidine option rather than ICD therapy, taking in account the high incidence of complications observed with ICD, some of them potentially lethal. 24 References 1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006; 48:e247 e Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, et al. Brugada syndrome: Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: Marquez MF, Salica G, Hermosillo AG, Pastelin G, Gomes-Flores J, Nava S. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18: Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita D. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007; 4: Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricular fibrillation: Inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987; 75: Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with class 1A antiarrhythmic drugs on long-term outcome in patients with idiopathic ventricular fibrillation and the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10: Belhassen B, Glick A, Viskin S. Efficacy of quinidine in highrisk patients with Brugada syndrome. Circulation 2004; 110: Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: Is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol 2002; 25: Belhassen B, Pelleg A, Miller HI, Laniado S. Serial electrophysiological studies in a young patient with recurrent ventricular fibrillation. Pacing Clin Electrophysiol 1981; 4: Belhassen B. A 25-year control of idiopathic ventricular fibrillation with electrophysiologic-guided antiarrhythmic drug therapy. Heart Rhythm 2004; 1: Belhassen B, Shapira I, Sheps D, Shoshani D, Laniado S. Programmed ventricular stimulation using up to two extrastimuli and repetition of double extrastimulation for induction of ventricular tachycardia: A new highly sensitive and specific protocol. Am J Cardiol 1990; 65: Viskin S, Antzelevitch C, Marquez MF, Belhassen B. Quinidine: A valuable medication joins the list of endangered species. Europace 2007; 9: Dock W. Transitory ventricular fibrillation as a cause of syncope and its prevention by quinidine sulfate. Am Heart J 1929; 4: Moe T. Morgagni-Adams-Stokes attacks caused by transient recurrent ventricular fibrillation in a patient without apparent heart disease. Am Heart J 1949; 37: Konty F, Dale J. Self-terminating idiopathic ventricular fibrillation presenting as syncope: A 40-year follow-up report. J Intern Med 1990; 227: Aizawa Y, Naitoh N, Washizuka T, Takahashi K, Uchiyama H, Shiba M, Shibata A. Electrophysiological findings in idiopathic recurrent ventricular fibrillation: Special reference to mode of induction, drug testing and long-term outcomes. Pacing Clin Electrophysiol 1996; 19: Wever EFD, Hauer RNW, Oomen A, Peters RHJ, Bakker PFA, Robles de Medina EO. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation 1993; 88: Otto C, Tauxe R, Cobb L, Greene HL, Gross BW, Werner JA, Burroughs RW, et al. Ventricular fibrillation causes sudden death in Southeast Asian immigrants. Ann Intern Med 1984; 100: Garg A, Finneran W, Feld GK. Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. J Cardiovasc Electrophysiol 1998; 9: Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: Low-dose quinidine therapy as 300 March 2009 PACE,Vol.32
8 QUINIDINE FOR IDIOPATHIC VF AND BRUGADA SYNDROME an adjunctive treatment. J Cardiovasc Pharmacol 2006; 47: Paul M, Gerss J, Schultze-Bahr E, Wichter T, Vahlhaus C, Wilde AA, Breithardt G, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: A meta-analysis of worldwide published data. Eur Heart J 2007; 28: Viskin S, Rogowski O. Asymptomatic Brugada syndrome: A cardiac ticking time-bomb? Europace 2007; 9: Rosso R, Glick A, Glikson M, Wagshal A, Swissa M, Rosenhek S, Shetboun I, et al. Outcome after implantation of cardioverter defibrillator in patients with Brugada syndrome: A multicenter Israeli study (ISRABRU). IMAJ 2008; 10: PACE,Vol.32 March
Brugada syndrome is a cardiac disease caused by an
Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome Bernard Belhassen, MD; Aharon Glick, MD; Sami Viskin, MD Background Automatic implantable cardioverter-defibrillator therapy is considered
More informationClinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation
J Arrhythmia Vol 25 No 1 2009 Original Article Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation Seiji Takashio
More informationElectrophysiologic investigation in Brugada syndrome
European Heart Journal (2002) 23, 1394 1401 doi:10.1053/euhj.2002.3256, available online at http://www.idealibrary.com on Electrophysiologic investigation in Brugada syndrome Yield of programmed ventricular
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationWhen VF is the endpoint, wait and see is not always the best option.
Being free of symptoms does not necessarily mean free of arrhythmias. This Holter is from a asymptomatic 48 years old female with LQT2 When VF is the endpoint, wait and see is not always the best option.
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationBernard Belhassen, MD; Roman Fish, MD; Sami Viskin, MD; Aharon Glick, MD; Michael Glikson, MD; Michael Eldar, MD
www.ipej.org 3 Original Article Incidence of Dual AV Node Physiology Following Termination of AV Nodal Reentrant Tachycardia by Adenosine-5'-Triphosphate: A Comparison with Drug Administration in Sinus
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationSyncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?
Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationA case of Brugada syndrome coexisting with vasospastic angina: Caution should be taken when using calcium channel blockers
Journal of Cardiology Cases (2011) 4, e143 e147 Available online at www.sciencedirect.com jou rn al h om epa g e: www.elsevier.com/locate/jccase Case Report A case of Brugada syndrome coexisting with vasospastic
More informationApproximately 5% of patients who experience sudden death
Sodium Channel Blockers Identify Risk for Sudden Death in Patients With ST-Segment Elevation and Right Bundle Branch Block but Structurally Normal Hearts Ramon Brugada, MD; Josep Brugada, MD; Charles Antzelevitch,
More informationVentricular tachycardia Ventricular fibrillation and ICD
EKG Conference Ventricular tachycardia Ventricular fibrillation and ICD Samsung Medical Center CCU D.I. Hur Ji Won 2006.05.20 Ventricular tachyarrhythmia ventricular tachycardia ventricular fibrillation
More informationThe Brugada Syndrome: An Easily Identified and Preventable Cause of Sudden Cardiac Death
The Brugada Syndrome: An Easily Identified and Preventable Cause of Sudden Cardiac Death Raymond Farah, MD 1, Elias Nassir, MD 2, Rola Farah, MD 3, Moshe Shai, MD 4 Nathan Roguin, MD 5 1 Department of
More informationReentry in a Pulmonary Vein as a Possible Mechanism of Focal Atrial Fibrillation
824 Reentry in a Pulmonary Vein as a Possible Mechanism of Focal Atrial Fibrillation BERNARD BELHASSEN, M.D., AHARON GLICK, M.D., and SAMI VISKIN, M.D. From the Department of Cardiology, Tel-Aviv Sourasky
More informationPause-induced Ventricular Tachycardia: Clinical Characteristics
Pause-induced Ventricular Tachycardia: Clinical Characteristics Margaret Bond A. Study Purpose and Rationale Until three decades ago, ventricular arrhythmias were thought to be rare in occurrence and their
More informationA historical outline of quinidine
Cuban Society of Cardiology Special Article A historical outline of quinidine Apunte histórico sobre la quinidina Margarita Dorantes Sánchez, MD Arrhythmia and Cardiac Pacing Department. Institute of Cardiology
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationIdiopathic Ventricular Tachycardia Need for an Update in EHRA/HRS Consensus?
Idiopathic Ventricular Tachycardia Need for an Update in EHRA/HRS Consensus? Arash Arya, M.D. Department of Interventional Electrophysiology Heart Center University of Leipzig Disclosures: NONE Idiopathic
More informationTailored treatment in Brugada syndrome
Tailored treatment in Brugada syndrome Lars Eckardt Department of Cardiology and Angiology Division of Experimental and Clinical Electrophysiology University of Münster, Germany 45 yr old male preoperative
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationUnusual Tachycardia Association In A patient Without Structural Heart Disease
www.ipej.org 233 Case Report Unusual Tachycardia Association In A patient Without Structural Heart Disease Eduardo Arana-Rueda, Alonso Pedrote, Lorena Garcia-Riesco, Manuel Frutos-Lopez, Juan A. Sanchez-Brotons
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationState of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification
State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification Lars Eckardt Division Electrophysiology Department of Cardiovascular Medicine University of Münster, Germany I have
More informationCase Report Coexistence of Atrioventricular Nodal Reentrant Tachycardia and Idiopathic Left Ventricular Outflow-Tract Tachycardia
www.ipej.org 149 Case Report Coexistence of Atrioventricular Nodal Reentrant Tachycardia and Idiopathic Left Ventricular Outflow-Tract Tachycardia Majid Haghjoo, M.D, Arash Arya, M.D, Mohammadreza Dehghani,
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationUse of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications
JACC Vol. 14, No. I July 1 8 1 5 5-61 155 ELECTROPHYSIOLOGIC STUDIES Use of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications RICHARD
More informationJ Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University
J Wave Syndromes Osama Diab Lecturer of Cardiology Ain Shams University J Wave Syndromes Group of electric disorders characterized by > 1 mm elevation of the J point or prominent J wave with or without
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationImplantable cardioverter defibrillator, Inappropriate shock, Lead failure
Inappropriate Discharges of Intravenous Implantable Cardioverter Defibrillators Owing to Lead Failure Takashi WASHIZUKA, 1 MD, Masaomi CHINUSHI, 1 MD, Ryu KAZAMA, 1 MD, Takashi HIRONO, 1 MD, Hiroshi WATANABE,
More informationfile://c:\documents and Settings\admin\My Documents\CV\92.htm
Page 1 of 5 Amir Farjam Fazelifar, M.D. Assistant Professor of Cardiac Electrophysiology Academic Address: Shaheed Rajaei Cardiovascular, Medical & Research Center, Vali- Asr Avenue Tehran- Iran Tel /
More informationP. Brugada 1, R. Brugada 2 and J. Brugada 3. Introduction. U.S.A.; 3 Unitat d Arritmias, Hospital Clinic, Barcelona, Spain
European Heart Journal (2000) 21, 321 326 Article No. euhj.1999.1751, available online at http://www.idealibrary.com on Sudden death in patients and relatives with the syndrome of right bundle branch block,
More informationOriginal Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy
4 Original Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy Sirin Apiyasawat, Dujdao Sahasthas, Tachapong Ngarmukos, Pakorn Chandanamattha, Khanchit Likittanasombat
More informationCase Report. Faculty of Medicine, Oita University 2 Department of Cardiology, Hakuaikai Hospital
Case Report Manifestation of ST-Segment Elevation in Right Precordial Leads during schemia at a Right Ventricular Outflow Tract rea in a Patient with rugada Syndrome Naohiko Takahashi MD 1, Tetsuji Shinohara
More informationPositive QRS Complex in Lead I as a Malignant Sign in Right Ventricular Outflow Tract Tachycardia
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Arrhythmia/Electrophysiology Positive QRS Complex in Lead I as a Malignant Sign in Right
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationAssessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis
Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationRipolarizzazione precoce. Torino, 24th October Non così innocente come si pensava
Asymptomatic inherited arrhythmia syndromes: Drug induced Brugada Syndrome: when a prophylactic ICD is indicated? how high (or low) is QT the risk? Asymptomatic short Ripolarizzazione precoce. Torino,
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationNEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS
NEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS OBJECTIVES Discuss history of ICDs Review the indications for ICD and CRT therapy Describe basic lead and device technology Discuss different therapies
More informationCase Presentation. Asaad Khan University College Hospital Galway Rep of Ireland
Case Presentation Asaad Khan University College Hospital Galway Rep of Ireland Case History 32 male Married Working as a chartered accountant P/C:Admitted to a Regional hospital to be investigated for
More informationTitle: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
More informationThe patient with (without) an ICD and heart failure: Management of electrical storm
ISHNE Heart Failure Virtual Symposium April 2008 The patient with (without) an ICD and heart failure: Management of electrical storm Westfälische Wilhelms-Universität Münster Günter Breithardt, MD, FESC,
More informationFANS Paediatric Pathway for Inherited Arrhythmias*
FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
More informationΔιαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada
Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας και Βηματοδότησης BrS: Diagnosis 5:10000 First described
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationOptimal management of Brugada syndrome
Optimal management of Brugada syndrome Cristian Stătescu 1,2, Teodor Vasilcu 1,2, Ioana Mădălina Chiorescu*,1,2, Grigore Tinică 1,2, Cătălina Arsenescu-Georgescu 1,2, Radu Sascău 1,2 1 "Grigore T. Popa"
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationMedical Policy Manual. Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement
Medical Policy Manual Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Date of Origin: February 5, 2003 Section: Durable Medical Equipment Last
More informationMEDICAL POLICY Cardioverter Defibrillators
POLICY........ PG-0224 EFFECTIVE......06/01/09 LAST REVIEW... 01/27/17 MEDICAL POLICY Cardioverter Defibrillators GUIDELINES This policy does not certify benefits or authorization of benefits, which is
More informationVagally mediated ventricular arrhythmia in Brugada syndrome
Vagally mediated ventricular arrhythmia in Brugada syndrome Nicholay Teodorovich, MD, FHRS, * Yonatan Kogan, MD, * Offir Paz, MD, * Moshe Swissa, MD, FHRS * From the * Department of Cardiology, Kaplan
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationIdiopathic Polymorphic Ventricular Tachycardia: a Benign Disease with a Touch of Bad Luck?
Review rticle Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Idiopathic Polymorphic Ventricular Tachycardia: a enign Disease with a Touch of ad Luck? Sami Viskin, MD Tel viv Sourasky
More informationInvasive Risk Stratification: When is it needed?
Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of
More informationTachycardias II. Štěpán Havránek
Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationInteractive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators
22 March 2002 Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators F. HINTRINGER, O. PACHINGER Division of Cardiology, Department for Internal Medicine, University
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationCase Report Simultaneous Accessory Pathway and AV Node Mechanical Block
185 Case Report Simultaneous Accessory Pathway and AV Node Mechanical Block Daniel Garofalo, MD, FRACP, Alfonso Gomez Gallanti, MD, David Filgueiras Rama, MD, Rafael Peinado Peinado, PhD, FESC Unidad de
More informationAppearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome
Appearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome Yasuaki Hada, MD, * Mitsuhiro Nishizaki, MD, * Noriyoshi Yamawake,
More informationAblative Therapy for Ventricular Tachycardia
Ablative Therapy for Ventricular Tachycardia Nitish Badhwar, MD, FACC, FHRS 2 nd Annual UC Davis Heart and Vascular Center Cardiovascular Nurse / Technologist Symposium May 5, 2012 Disclosures Research
More informationShort QT Syndrome: Pharmacological Treatment
Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.034
More informationAsymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱
Asymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱 Let It Be? Vs. Just Do It? Natural history of asymptomatic WPW Incidence of sudden cardiac death in natural history studies involving
More informationRemote Monitoring & the Smart Home of the 21 Century
Cardiostim EHRA Europace 2016, Nice - June 8-11, 2016 Remote Monitoring & the Smart Home of the 21 Century Antonio Raviele, MD, FESC, FHRS President ALFA -Alliance to Fight Atrial fibrillation- Venezia
More informationQuinidine for Brugada syndrome: Panacea or poison?
Quinidine for Brugada syndrome: Panacea or poison? Jo-Jo Hai, MBBS, * Chun-Ka Wong, MBBS, * Pak-Hei Chan, MBBS, * Hung-Fat Tse, MD, PhD, * Tak-Cheung Yung, MBBS, Chung-Wah Siu, MD From the * Division of
More informationMedicine. Dynamic Changes of QRS Morphology of Premature Ventricular Contractions During Ablation in the Right Ventricular Outflow Tract
Medicine CLINICAL CASE REPORT Dynamic Changes of QRS Morphology of Premature Ventricular Contractions During Ablation in the Right Ventricular Outflow Tract A Case Report Li Yue-Chun, MD, Lin Jia-Feng,
More informationTreatment of VT of Purkinje fiber origin: ablation targets and outcome
Treatment of VT of Purkinje fiber origin: ablation targets and outcome Ch. Piorkowski University Leipzig - Heart Center - Dept. of Electrophysiology Leipzig, Germany Presenter Disclosure Information Gerhard
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationHow to manage a patient with short QT syndrome?
How to manage a patient with short QT syndrome? Torino, 27 ottobre2012 Carla Giustetto Division of Cardiology University of Torino QT 280 ms QTc 260 ms Narrow, tall and peaked T waves High incidence of
More informationVentricular arrhythmias
Ventricular arrhythmias Assoc.Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University HospitalMotol and2nd FacultyofMedicine, Charles University in Prague Definition and classification Ventricular
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationOutflow Tract Ventricular Tachycardia Always Benign?
Outflow Tract Ventricular Tachycardia Always Benign? Arash Arya, M.D. Department of Interventional Electrophysiology Heart Center University of Leipzig Disclosures: NONE Outflow Ventricular Tachycardia
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ
ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ ΣΤΕΛΙΟΣ ΠΑΡΑΣΚΕΥΑÏΔΗΣ ΔΙΕΥΘΥΝΤΗΣ ΕΣΥ Α Καρδιολογική Κλινική ΑΠΘ, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη NO CONFLICT OF INTEREST Sudden Cardiac Death
More informationSIGNIFICANCE OF INDUCIBLE VENTRICULAR FLUTTER - FIBRILLATION AFTER MYOCARDIAL INFARCTION.
! 1 SIGNIFICANCE OF INDUCIBLE VENTRICULAR FLUTTER - FIBRILLATION AFTER MYOCARDIAL INFARCTION. Béatrice Brembilla-Perrot Cardiology, CHU of Brabois, Vandoeuvre, France Adress for correspondence : B Brembilla-Perrot,
More informationAugmented ST-Segment Elevation During Recovery From Exercise Predicts Cardiac Events in Patients With Brugada Syndrome
Journal of the American College of Cardiology Vol. 56, No. 19, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.201.033 Heart
More informationAsaad Khoury 2,3 MD, Monther Boulos 1,3 MD, Mahmoud Suleiman 1,3 MD, Miry Blich 1,3 MD, Michael Eldar 4 MD, Ibrahim Marai 1,3 MD,
Flecainide therapy suppresses exercise induced ventricular arrhythmias in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD,
More informationVentricular arrhythmias in acute coronary syndromes. Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital
Ventricular arrhythmias in acute coronary syndromes Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital introduction myocardial ischaemia and infarction leads to severe
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationMEDICINAL PRODUCTS FOR THE TREATMENT OF ARRHYTHMIAS
MEDICINAL PRODUCTS FOR THE TREATMENT OF ARRHYTHMIAS Guideline Title Medicinal Products for the Treatment of Arrhythmias Legislative basis Directive 75/318/EEC as amended Date of first adoption November
More informationRisk Stratification for Asymptomatic Patients With Brugada Syndrome
Circ J 2003; 67: 312 316 Risk Stratification for Asymptomatic Patients With Brugada Syndrome Prediction of Induction of Ventricular Fibrillation by Noninvasive Methods Hiroshi Morita, MD; Shiho Takenaka-Morita,
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationICD: Basics, Programming and Trouble-shooting
ICD: Basics, Programming and Trouble-shooting Amir AbdelWahab, MD Electrophysiology and Pacing Service Cardiology Department Cairo University Feb 2013 Evolution of ICD Technology ICD Evolution Indications
More informationHow agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona
How agressively should we treat asymptomatic patients with Brugada syndrome Josep Brugada Medical Director Hospital Clínic, University of Barcelona The ECG in Brugada syndrome - Prolonged PR - RBBB - ST
More informationInappropriate electrical shocks: Tackling the beast
ESC Paris 2011 Inappropriate electrical shocks: Tackling the beast Gerhard Hindricks University of Leipzig Heart Center Dept. of Electrophysiology ESC Paris 2011 Inappropriate electrical shocks: Tackling
More informationEmergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013
Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013 Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the
More informationThe Brugada Syndrome*
Journal of the American College of Cardiology Vol. 51, No. 12, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.006
More information